The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market is estimated to be valued at US$ 1,282.14 Mn in 2022 and is expected to exhibit a CAGR of 31.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, life-threatening disease characterized by the buildup of abnormal deposits of misfolded transthyretin protein (amyloid) in the heart muscle. These amyloid deposits interfere with the normal functioning of the heart and may lead to heart failure or abnormal heart rhythms. Currently available treatments for ATTR-CM aim to slow or halt the progression of the disease. ATTR-CM treatment options include tafamidis, which act to stabilize the transthyretin protein. Improved diagnostic techniques are enabling earlier identification and treatment of ATTR-CM patients.
Market key trends:
One of the key trends in the ATTR-CM treatment market is the launch of new therapies by major players. In 2019, Pfizer launched Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for the treatment of ATTR-CM. These are the first and only approved therapies that specifically target transthyretin stabilization for the treatment of the disease. The approval and launch of new medications is expected to significantly drive the growth of the ATTR-CM treatment market over the forecast period. Currently several pharmaceutical companies are conducting trials for new product candidates to treat ATTR-CM. Positive results from ongoing late stage clinical trials can translate into regulatory approvals and subsequent launch of new therapies, further boosting the market.
Threat of new entrants: Low, as there are several regulatory approvals and the market already has strong competitors with established distribution channels.
Bargaining power of buyers: Moderate, as there are few existing approved treatment options for ATTR-CM, buyers have some bargaining power.
Bargaining power of suppliers: Moderate, as the key technology suppliers have their proprietary technologies, buy the dependence on such suppliers is also high.
Threat of new substitutes: Moderate, as new alternative therapies for ATTR-CM are under clinical trials which can emerge as substitutes.
Competitive rivalry: High, as the major players are focusing on developing innovative therapies and target new geographical regions to stay ahead of competition.
The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size is expected to witness high growth, exhibiting CAGR of 31.1% over the forecast period, due to increasing R&D investment in development of novel disease-modifying therapies.
North America is expected to dominate the global ATTR-CM treatment market during the forecast period. This is attributed to growing diagnosis rate of ATTR-CM, strong presence of key market players, and favorable reimbursement scenario in the region. However, Asia Pacific is anticipated to exhibit the fastest growth rate over the coming years owing to increasing healthcare spending and rising awareness about hereditary ATTR amyloidosis in major Asian countries.
Key players operating in the ATTR-CM treatment market are Pfizer Inc., GlaxoSmithKline Plc., Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc. Major companies are focused on conducting clinical trials to develop disease-modifying therapies with improved safety and efficacy profiles.